SEC Comment Letter for ARTELO BIOSCIENCES, INC. (ARTL) (CIK 0001621221) (ARTL) — May 11, 2026
ARTELO BIOSCIENCES, INC. (ARTL) (CIK 0001621221)
Date: May 11, 2026 · CIK: 0001621221 · Accession: 0000000000-26-004788
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295537
Letter
May 11, 2026 Gregory D. Gorgas Chief Executive Officer Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 Re: Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed May 04, 2026 File No. 333-295537 Dear Gregory D. Gorgas: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Amanda I. Hawthorne, Esq.
Show Raw Text
May 11, 2026 Gregory D. Gorgas Chief Executive Officer Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 Re: Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed May 04, 2026 File No. 333-295537 Dear Gregory D. Gorgas: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Amanda I. Hawthorne, Esq.